Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 30, 2021	Apr. 15, 2021
Aggregate number of common shares issued	19,478,270		19,478,270			9,625,133	6,666,666
Common stock shares issued price per share							$ 3
common stock shares authorized							300,000,000
Issued and outstanding shares of common stock ownership percentage							70.30%
Assets purchase agrement	$ 26,000,000		$ 26,000,000
Development expenses	1,834,786	$ 646,798	5,047,096	$ 646,798
Property assets	39,081,822		39,081,822		$ 40,822,161
Accounts receivable	400,198		400,198		0
Ainos COVID-19 Test Kits Sales and Marketing Agreement with Ainos KY
Totaling			1,603,169	173,657
Accounts payable	24,242		24,242		0
Product Co-development Agreement [Member]
Assets purchase agrement	29,542,959		29,542,959
Convertible	800,000		800,000		981,000
Development expenses			490,082	117,386
Accrued payables	21,594		21,594		65,156
Property assets	24,886,023		24,886,023
Equipment	1,113,977		1,113,977
Notes payble	376,526	$ 505,931	376,526	505,931
Convertible note	69,025		69,025		145,395
Non convertivle notes payble	129,405		129,405
COVID-19 Antigen Rapid Test Kits Sales
Totaling			1,988,150	$ 185,376
Accounts receivable	335,799		335,799		0
Ase Test Inc. [Member]
Assets purchase agrement	26,000,000		26,000,000
Convertible	800,000		800,000		$ 3,000,000
Principal amount	$ 500,000		$ 500,000